SCHEMBL74254

SCHEMBL74254

CCc1cccc(CC)c1-c1ncc(CN(C)[C@H]2CCCc3ccccc32)c(N(C)C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
C5AR1 P21730 5/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
P4HB P07237 1/20 0.37
RAB9A P51151 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
CXCR4 P61073 2/20 0.35
TSHR P16473 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TAS2R14 Q9NYV8 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
ADRB2 P07550 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL61192 0.86 ALDH1A1 (0.39) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL74248 0.82 MEN1 (0.37) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL64660 0.82 ALDH1A1 (0.42) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL61468 0.79 MEN1 (0.38) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL62223 0.79 ALDH1A1 (0.40) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL62704 0.78 MEN1 (0.40) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL61966 0.78 ALDH1A1 (0.41) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL61967 0.78 ALDH1A1 (0.41) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL61148 0.78 ALDH1A1 (0.41) ALDH1A1XBP1HTTC5AR1MEN1
SCHEMBL61147 0.78 ALDH1A1 (0.41) ALDH1A1XBP1HTTC5AR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-8129395-B2 4,5-disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-03-06 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022516-A1 4,5-Disubstituted-2-aryl pyrimidines C5AR2, C5AR1, C3AR1 ALDH1A1 1684/4885XBP1 2718/4885HTT 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.